Our Hong Kong office has acted as the Cayman Islands and British Virgin Islands legal counsel of Sipai Health Technology Co. Ltd. in connection with its approximately HK$120 million initial public offering and listing of its 763,025,314 shares (assuming the over-allotment option is not exercised) on the Main Board of the Hong Kong Stock Exchange.
O'Melveny & Myers and Jingtian & Gongcheng acted as Hong Kong and PRC legal counsel, respectively, to Sipai Health Technology Co. Ltd. Clifford Chance and Commerce & Finance Law Offices acted as Hong Kong and PRC legal counsel, respectively, to Morgan Stanley Asia Limited and Haitong International Capital Limited (being the joint sponsors) and the underwriters (including Morgan Stanley Asia Limited, Haitong International Securities Company Limited, Futu Securities International (Hong Kong) Limited, Maxa Capital Limited and I Win Securities Limited).
Sipai Health Technology Co. Ltd. is a company dedicated to connect and deliver clear values to patients, doctors, medical institutions, pharmaceutical companies and payers across China's healthcare system through its robust technology platform and data-enabled operational capabilities. It currently runs three business lines, including Specialty Pharmacy Business, Physician Research Assistance and Health Insurance Services.
Partner Jenny Nip led the transaction with support from Chantelle Chan and Ben Tao.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.